This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Friday's Health Winners & Losers

CryoCor (CRYO) celebrated another gain, while it was overall a flat-to-down biotech day.

After a rally yesterday tied to a pre-market approval, CryoCor took to gaining again on Friday after announcing a deal with Boston Scientific (BSX). The companies will co-develop a console to deliver cryo energy, which uses extreme cold, to Boston Scientific's cryo balloon catheter to treat atrial fibrillation. CryoCor will develop and potentially manufacture the consoles, which will be used with Boston Scientific's internally developed catheter balloons, according to the companies.

Boston Scientific will make payments tied to development milestones, and also sale-based royalties, in addition to purchasing 2.5 million of CryoCor's stock. It will also purchase another $2.5 million tied to development milestones.

CryoCor climbed 84 cents, or 17.5% to $5.65, after rising more than 20% earlier in the day, while Boston Scientific tiptoed in the red 16 cents, or 1%, to $15.34.

Ziopharm (ZIOP) presented gene-profiling data and interim phase II trial data for advanced myeloma treatment darinaparsin throughout the week at the Annual Myeloma Workshop in Greece. The company was up 40 cents, or 8.4%, to $5.15.

On the flipside, Antares Pharma (AIS) bled 15 cents, or 8.6%, to $1.60 on Friday after announcing that it will privately place $15 million in newly issued common stock and warrants for additional shares with institutional and other investors. The company said the financing is expected to close after it gets Amex approval.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs